BRPI0919842A2 - Tratamento de neuroblastioma com conjugados poliméricos de múltiplos braços de 7-etil-10-hidroxicamptotecina - Google Patents
Tratamento de neuroblastioma com conjugados poliméricos de múltiplos braços de 7-etil-10-hidroxicamptotecinaInfo
- Publication number
- BRPI0919842A2 BRPI0919842A2 BRPI0919842-3A BRPI0919842A BRPI0919842A2 BR PI0919842 A2 BRPI0919842 A2 BR PI0919842A2 BR PI0919842 A BRPI0919842 A BR PI0919842A BR PI0919842 A2 BRPI0919842 A2 BR PI0919842A2
- Authority
- BR
- Brazil
- Prior art keywords
- neuroblastioma
- hydroxycamptothecin
- ethyl
- treatment
- polymeric conjugates
- Prior art date
Links
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10717508P | 2008-10-21 | 2008-10-21 | |
US17028509P | 2009-04-17 | 2009-04-17 | |
PCT/US2009/060765 WO2010048018A1 (en) | 2008-10-21 | 2009-10-15 | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0919842A2 true BRPI0919842A2 (pt) | 2015-08-18 |
BRPI0919842A8 BRPI0919842A8 (pt) | 2015-09-22 |
Family
ID=42108845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0919842A BRPI0919842A8 (pt) | 2008-10-21 | 2009-10-15 | tratamento de neuroblastioma com conjugados poliméricos de múltiplos braços de 7-etil-10-hidroxicamptotecina |
Country Status (10)
Country | Link |
---|---|
US (1) | US20100098654A1 (pt) |
EP (1) | EP2341774B1 (pt) |
JP (1) | JP2012506380A (pt) |
KR (1) | KR20110075029A (pt) |
CN (1) | CN102215688A (pt) |
AU (1) | AU2009307922A1 (pt) |
BR (1) | BRPI0919842A8 (pt) |
CA (1) | CA2738807A1 (pt) |
TW (1) | TW201016237A (pt) |
WO (1) | WO2010048018A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120044925A (ko) * | 2009-04-17 | 2012-05-08 | 엔즌 파마슈티칼스, 인코포레이티드 | 7-에틸-10-하이드록시캄토테신의 다중-가지 고분자 복합체를 이용한 신생혈관형성 억제 방법 |
US8709420B2 (en) * | 2010-12-17 | 2014-04-29 | Glaxosmithkline Intellectual Property Limited | Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human |
TWI716342B (zh) * | 2013-10-04 | 2021-01-21 | 美商普洛林克斯有限責任公司 | Sn-38之緩釋結合物 |
MX2016004609A (es) | 2013-10-15 | 2016-08-01 | Seattle Genetics Inc | Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco. |
SG11201804268RA (en) | 2015-12-04 | 2018-06-28 | Seattle Genetics Inc | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11844839B2 (en) | 2016-03-25 | 2023-12-19 | Seagen Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
EP3348560A1 (en) * | 2017-01-16 | 2018-07-18 | Spago Nanomedical AB | Chemical compounds for coating of nanostructures |
CN110430901A (zh) | 2017-03-24 | 2019-11-08 | 西雅图基因公司 | 制备葡糖苷酸药物-接头及其中间体的方法 |
US20200360545A1 (en) | 2018-01-12 | 2020-11-19 | Prolynx Llc | Protocol for minimizing toxicity of combination dosages and imaging agent for verification |
AU2019344783A1 (en) * | 2018-09-17 | 2021-04-08 | The Children's Hospital Of Philadelphia | Polymer-based macromolecular prodrugs |
JP7226732B2 (ja) * | 2018-11-12 | 2023-02-21 | 国立大学法人東海国立大学機構 | 尿中腫瘍マーカーによるがん検出方法、キット及び装置 |
CN115298189A (zh) | 2019-12-04 | 2022-11-04 | 丹塔里股份有限公司 | 合成治疗性纳米颗粒的方法和组合物 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4473692A (en) * | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
AU4406793A (en) * | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US5614549A (en) * | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5965566A (en) * | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5840900A (en) * | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5605976A (en) * | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US5736156A (en) * | 1995-03-22 | 1998-04-07 | The Ohio State University | Liposomal anf micellular stabilization of camptothecin drugs |
TW438775B (en) * | 1995-04-07 | 2001-06-07 | Pharmacia & Upjohn Co Llc | Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
JPH10168373A (ja) * | 1996-12-12 | 1998-06-23 | Fuji Xerox Co Ltd | インクジェット記録用インク及びそれを用いる記録方法 |
JP3855344B2 (ja) * | 1997-02-19 | 2006-12-06 | 日本油脂株式会社 | ポリオキシアルキレンカルボン酸の製造方法 |
US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
US6111107A (en) * | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
US5968748A (en) * | 1998-03-26 | 1999-10-19 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human HER-2 expression |
US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6897200B1 (en) * | 1998-10-14 | 2005-05-24 | University Of Kentucky Research Foundation | Oligonucleotide delivery systems for camptothecins |
AU780119B2 (en) * | 1999-01-06 | 2005-03-03 | Cornell Research Foundation Inc. | Accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing |
US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
WO2000066125A1 (en) * | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
CN1607962A (zh) * | 1999-10-12 | 2005-04-20 | 细胞治疗公司 | 聚谷氨酸-治疗剂结合物的生产方法 |
DK1259562T3 (da) * | 1999-12-22 | 2006-04-18 | Nektar Therapeutics Al Corp | Sterisk hindrede derivater af vandoplöselige polymerer |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
US6632818B2 (en) * | 2000-01-12 | 2003-10-14 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU2001257577A1 (en) * | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
WO2001070275A2 (en) * | 2000-03-17 | 2001-09-27 | Cell Therapeutics, Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
US6756037B2 (en) * | 2000-03-31 | 2004-06-29 | Enzon, Inc. | Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups |
JP2004514701A (ja) * | 2000-11-30 | 2004-05-20 | ネクター セラピューティクス エーエル,コーポレイション | トリアジン誘導体の水溶性ポリマー複合体 |
US20020123401A1 (en) * | 2001-03-02 | 2002-09-05 | Henry Rassem Ragheb | Combination starter-generator |
US20080188430A1 (en) * | 2001-05-18 | 2008-08-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
JP4123856B2 (ja) * | 2001-07-31 | 2008-07-23 | 日油株式会社 | 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法 |
US6608076B1 (en) * | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
JP2005529938A (ja) * | 2002-06-06 | 2005-10-06 | ユニバーシティ オブ ワシントン | 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 |
MX367615B (es) * | 2002-09-06 | 2019-08-28 | Cerulean Pharma Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
US6649778B1 (en) * | 2002-09-20 | 2003-11-18 | Enzon, Inc. | Methods of preparing amino acid taxane derivatives and polymer conjugates containing the same |
WO2004032925A1 (en) * | 2002-10-11 | 2004-04-22 | Novartis Ag | Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents |
US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
DK1581174T3 (en) * | 2002-12-16 | 2018-06-18 | Globeimmune Inc | Yeast-based vaccines such as immunotherapy |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
US8394365B2 (en) * | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
US7744861B2 (en) * | 2003-09-17 | 2010-06-29 | Nektar Therapeutics | Multi-arm polymer prodrugs |
US20050214250A1 (en) * | 2003-11-06 | 2005-09-29 | Harris J M | Method of preparing carboxylic acid functionalized polymers |
US20050215503A1 (en) * | 2003-12-03 | 2005-09-29 | Mcevoy Leslie M | HIF oligonucleotide decoy molecules |
AU2005222641B2 (en) * | 2004-03-15 | 2011-04-07 | Nektar Therapeutics | Polymer-based compositions and conjugates of HIV entry inhibitors |
CA2561111A1 (en) * | 2004-03-26 | 2005-10-13 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer |
US7989554B2 (en) * | 2006-01-10 | 2011-08-02 | Enzon Pharmaceuticals, Inc. | Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
AU2007212201B2 (en) * | 2006-02-09 | 2012-09-13 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
WO2008089388A2 (en) * | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
AU2008213576B2 (en) * | 2007-02-09 | 2013-01-17 | Enzon Pharmaceuticals, Inc. | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
CA2689602A1 (en) * | 2007-06-06 | 2008-12-18 | Avi Biopharma, Inc. | Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease |
-
2009
- 2009-10-15 US US12/579,614 patent/US20100098654A1/en not_active Abandoned
- 2009-10-15 WO PCT/US2009/060765 patent/WO2010048018A1/en active Application Filing
- 2009-10-15 CN CN2009801419594A patent/CN102215688A/zh active Pending
- 2009-10-15 JP JP2011532237A patent/JP2012506380A/ja active Pending
- 2009-10-15 EP EP09822452.0A patent/EP2341774B1/en not_active Not-in-force
- 2009-10-15 CA CA2738807A patent/CA2738807A1/en not_active Abandoned
- 2009-10-15 BR BRPI0919842A patent/BRPI0919842A8/pt not_active IP Right Cessation
- 2009-10-15 AU AU2009307922A patent/AU2009307922A1/en not_active Abandoned
- 2009-10-15 KR KR1020117011696A patent/KR20110075029A/ko not_active Application Discontinuation
- 2009-10-20 TW TW098135368A patent/TW201016237A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010048018A1 (en) | 2010-04-29 |
AU2009307922A1 (en) | 2010-04-29 |
TW201016237A (en) | 2010-05-01 |
EP2341774B1 (en) | 2013-12-04 |
JP2012506380A (ja) | 2012-03-15 |
KR20110075029A (ko) | 2011-07-05 |
EP2341774A4 (en) | 2012-03-28 |
CN102215688A (zh) | 2011-10-12 |
BRPI0919842A8 (pt) | 2015-09-22 |
EP2341774A1 (en) | 2011-07-13 |
CA2738807A1 (en) | 2010-04-29 |
US20100098654A1 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0919842A8 (pt) | tratamento de neuroblastioma com conjugados poliméricos de múltiplos braços de 7-etil-10-hidroxicamptotecina | |
BRPI0910259A2 (pt) | métodos de tratamento de inflamação | |
SMT201500014B (it) | Coniugati polimerici del fattore VIII | |
BRPI0910854A2 (pt) | métodos de tratamento | |
DK2337597T3 (da) | Medicinsk injektor med koblede legemsenheder | |
BRPI0917557A2 (pt) | artigo absorvente com componente de barreira | |
DK2452709T3 (da) | Kanyledel | |
DK2245130T3 (da) | Ts23 -alpha-amylasevarianter med ændrede egenskaber | |
BRPI0920514A2 (pt) | infusão de fármacos | |
BRPI0915310A2 (pt) | dispositivo de injeção | |
BRPI0915738A2 (pt) | composição de polímero reticulável | |
BRPI0922629A2 (pt) | dispositivo de injeção | |
BRPI0916931A2 (pt) | agentes terapêuticos | |
DK2330887T3 (da) | Behandlingsindretning | |
BRPI0918249A2 (pt) | prótese | |
BRPI0909416A2 (pt) | Utensílios médicos com revestimentos hidrofílicos | |
DK2081950T3 (da) | Med irinotecanbehandling forbundne ekspressionsprofiler | |
DK2265296T3 (da) | Medicinske apparater med hydrofile belægninger | |
DK3150178T3 (da) | Stimuleringsapparat | |
IT1392670B1 (it) | Iniettore | |
BRPI0920743A2 (pt) | ribonucleases terapeuticas | |
DK2376121T4 (da) | Slidgigtbehandling | |
DE112009000350A5 (de) | Einspritzvorrichtung | |
BRPI0909096A2 (pt) | uso de conjugados de interleicna-1 no tratamento de diabetes | |
DE112009003312A5 (de) | Implantat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |